Loading the session
Loading the session
Loading instrument
$13.83
+0.00%DelayedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 21:14 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
Closed at $13.83 on 4 Nov 2026: 0.4% below the 52-week high of $13.88 (4 Nov 2026) and 143.1% above the low of $5.69 (30 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
1 month: +0.7% (SPY −1.6%). 3 months: +1.9% (SPY −0.4%). 1 year: +112.1% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: OGN, SPY · as of 4 Nov 2026
18.8M shares were sold short at the 15 Oct 2026 settlement, 7.2% of the 262.6M shares outstanding; covering them would take 8.6 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $13.83 was 0.6% above its 50-day average ($13.74) and 19.3% above its 200-day average ($11.59). It has closed above the 200-day for 145 sessions, since 10 Apr 2026. The 50-day average crossed above the 200-day on 12 May 2026, 122 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
$0.02 a share, payable 10 Dec 2026; unchanged from the previous payment (ex-date 14 Aug 2026).
Corporate actions record · as of 5 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
April 24, 2026
+30.93%April 10, 2026
+27.79%May 1, 2025
−26.91%